Gilead Sciences Announces First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Gilead Sciences (GILD) PT Lowered to $76 at Barclays
April 29, 2024 5:23 AM EDTBarclays analyst Carter Gould lowered the price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $80.00) while maintaining a Equalweight rating.
The analyst comments "'25 HIV zero-growth messaging, puts onus on cell therapy and seladelpar launch to deliver overall top-line growth. Focus... More



